October 21, 2014 11:25 AM ET

Biotechnology

Company Overview of Asmacure Ltée

Company Overview

Asmacure Ltée, a clinical-stage biopharmaceutical company, focuses on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory respiratory diseases. It develops ASM-024, a molecular entity for the treatment of asthma. The company was founded in 2002 and is based in Quebec City, Canada.

2600, Boulevard Laurier

Suite 880

Quebec City, QC G1V 4W2

Canada

Founded in 2002

Phone:

418-780-4255

Fax:

418-781-0216

Key Executives for Asmacure Ltée

Chief Executive Officer and Director
Age: 55
Vice President of Finance and Administration
Vice President of Pre-Clinical Research and Development
Vice President of Corporate Affairs & Planning
Compensation as of Fiscal Year 2014.

Asmacure Ltée Key Developments

Asmacure Ltee Announces Clinical Update for Asmacure Ltee in Two Phase 2 Trials

Asmacure Ltee announced that the company has completed dosing in a Phase 2 trial evaluating its lead compound, ASM-024, in moderate asthma patients, with data anticipated in the first quarter of 2014. The company also has begun patient enrollment in a Phase 2 trial of ASM-024 in patients with moderate and severe chronic obstructive pulmonary disease (COPD). The recently completed Phase 2 asthma trial is a randomized, double-blind, placebo-controlled study with a primary outcome designed to evaluate the safety, tolerability, and dose selection of the ASM-024 dry powder for inhalation (DPI) dosage form in 15 patients with moderate asthma. The Phase 2 COPD trial is a randomized, double-blind, placebo-controlled, two-way crossover study designed to evaluate clinical outcomes and safety of the ASM-024 DPI dosage form in approximately 15 patients with GOLD 2 and GOLD 3 COPD. Each patient will be dosed for two weeks in each treatment period of the two-way crossover design. Data from this trial are expected in the third quarter of 2014. ASM-024's novel multi-functional mechanism of action involves effects at the nicotinic and muscarinic levels. Previous studies have shown that ASM-024 solution formulation induced smooth muscle relaxation as well as anti-inflammatory and bronchodilating effects, which may address an unmet medical need as an adjunctive treatment with current standard of care in patients with moderate to severe asthma and COPD. The precise mechanisms of action of ASM-024 continue to be studied.

Similar Private Companies By Industry

Company Name Region
Coeur Metrics Inc. Americas
Natrix Separations, Inc. Americas
Mimetogen Pharmaceuticals Inc. Americas
BioLipids Inc. Americas
Marsala Biotech Inc. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Asmacure Ltée, please visit www.asmacure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.